South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
The BioIndustry Association (BIA) has published new data revealing that the UK’s life sciences sector attracted £1.23 billion ($1.66 billion) in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total. 28 July 2025
TCG Labs Soleil has secured another $400 million to expand its global R&D footprint and help build out its growing portfolio of single-asset biotechnology companies. The San Francisco-based venture firm said the new fund matches the size of its inaugural raise last year. 25 July 2025
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. 23 July 2025
Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant. 23 July 2025
Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million Series D financing. 23 July 2025
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 13 July 2025
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, has announced the closing of a $120 million Series C financing round. 12 December 2024
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Dutch biotech Citryll, which is focused on treating immune-mediated inflammatory diseases by targeting neutrophil extracellular traps (NETs), today announced the successful closing of an oversubscribed 85 million euros ($89.8 million) Series B fundraise. 9 December 2024
Menlo Park-based Nuvig Therapeutics has raised $161 million in a series B financing round co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners. 6 December 2024
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Danish drug developer Antag Therapeutics, which is pioneering novel treatments for obesity, today announced the closing of an 80 million euros ($83.8 million) Series A financing. 4 December 2024
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant Novartis in frontline metastatic breast cancer. 3 December 2024
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
German family-owned pain focused drugmaker Grünenthal has announced the pricing of 500 million-euro ($527.5 million) aggregate principal amount of 4.625% senior secured notes due 2031. 29 November 2024
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024